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Objective:  Multiple studies have found between 18-70% of medical professionals 
prescribe placebos, with general practitioners’ (GPs) reportedly being the highest prescribers. 
Even though placebos are common in clinical practice, patients and doctors alike have issues 
with the deceit involved, which is resolved with open-label placebos. The study looked at GPs 
attitudes towards traditional placebos and open-label placebos. 
Method: Participants were practising GPs in Australia (N = 54). The study involved an 
online questionnaire composed of four different sections; demographics, attitudes towards 
traditional placebos and open-label placebos, understanding towards open-label placebo 
mechanisms and usage, and any concerns or comments they had towards open-label placebos.  
Results:  Differences found between traditional placebos and open-label placebos only 
involved GPs who were accepting of placebo interventions. GPs understanding of the underlying 
mechanisms being psychological and involving the patient/doctor relationship is in line with the 
current literature. The situational usage of open-label placebos in cases of non-specific or 
physical symptoms match with conditions commonly presented to GPs. The likelihood to 
prescribe open-label placebos did not appear to be influenced by demographic variables. The 
highest number of concerns and comments reported regarded patient acceptability and the lack of 
research in clinical practice.  
Conclusion: This exploratory analysis has constructed an overview of general 
practitioners’ attitudes towards placebos in Australia. Future research conducted with larger 
samples would be beneficial to evaluate demographic influences and the practicality of open-
label placebos. This study indicated that open-label placebos are a viable treatment option in 
clinical practice pending further research.  
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Chapter 1: Introduction 
1.1 Background 
The World Health Organization (1948) defines health as “a state of complete physical, 
mental, and social well-being, and not merely the absence of disease or infirmity”. When the 
health of a person is compromised, modern medicine often turns to treatment of a 
pharmacological nature, as it has become an integral part of medical practice (Fox, 2003). Whilst 
there are numerous benefits to this system, it does come at a financial cost to the patient, as well 
as the Australian Government (Fox, 2003). The Australian Government subsidises many 
commonly available drugs through the Pharmaceutical Benefits Scheme (Fox, 2003). This cost is 
growing and in 2016/17, it was to the tune of $12,058 million (Department of Health, 2017). 
Pharmacological treatment also has the risk of side effects (Howick et al, 2013). For example, 
the common best practice for treatment of chronic pain involves medications such as non-
steroidal anti-inflammatory drugs (NSAIDs), which can have harmful side effects (Ward, 
Archambault & Mersfelder, 2010). Harmful side effects include stomach problems, kidney 
problems, high blood pressure, and heart problems (Turner & Connolly, 2018). Additionally, 
when medication, such as antibiotics, are taken frequently or incorrectly, there runs the risk of 
the emergence of bacterial antibiotic resistance (Ventola, 2015). Bacterial antibiotic resistance is 
becoming a significant problem due to the expensive, albeit lengthy, cost of treatment, and the 
creation of new medication (Ventola, 2015). As a result, other treatment options are being 
investigated as an alternative or adjunct to pharmacological treatment. One such treatment 
option, particularly those of a more holistic nature, lies in the realm of placebos and harnessing 
their effect as a way to lead to better health outcomes. 
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  In this exploratory analysis, attitudes towards the use of placebos in clinical practice by 
general practitioners in Australia will be investigated. A summary of the research on the 
definition and mechanisms of placebos will be presented, followed by the current clinical use, 
attitudes and concerns towards them. The newly proposed open-label placebos (placebos without 
deception) will be introduced and the current literature regarding it will be reported. The overall 
aim is to examine general practitioners’ attitudes towards open-label placebos, to begin building 
the picture of what is currently understood about them and offer direction for future research.  
 
1.2 Definition of placebos 
The definition of placebos in clinical practice is hard to define as it varies considerably in 
the literature (Colloca & Howick, 2018). For the purpose of this literature review, a commonly 
used definition of placebos is ‘any intervention or treatment that objectively is known to have no 
specific effect, but for which a beneficial outcome occurs as a result of the patient believing in its 
efficacy’ (De Deyn & D’Hooge, 1996). Part of the ambiguity around defining placebos is due to 
the ‘placebo effect’ and ‘placebo response’ often being lumped in the same category (Kirsch, 
2013). A placebo response is an observable change following the administration of the placebo 
and typically utilised in clinical trials (Chaplin, 2006). On the other hand, a placebo effect is the 
change produced by the placebo treatment (Kirsch, 2013). It is the difference between the 
placebo response and no treatment (Howick et al., 2013).  
The placebo effect varies depending on the condition or illness making it difficult to 
determine the overall effectiveness of placebos. Conditions reported as having the strongest 
placebo effects involve the pain reduction and insomnia (Kisaaltita, Staud, Hurley & Robinson, 
2014; Yeung, Sharpe, Glozier, Hackett & Colagiuri, 2018). However, can also be found in 
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nausea, fibromyalgia, fatigue, and mood disorders have also been found (Chen et al., 2017; Cho, 
Hotopf & Wessely, 2005; Li, Li & Zheng, 2017; Quinn & Colagiuri, 2015). The placebo 
phenomenon also extends cross culturally. In African and South American cultures, healing 
rituals and herbal concoctions are commonly used when someone is ill, which are likened to 
placebo treatments in western medicine (Jara, 2014; Zimba & Buggie, 1993). 
 
1.3 The mechanisms underlying the placebo effect 
There are a few underlying mechanisms proposed to underlie the placebo effect. The 
most strongly researched mechanism is the classical conditioning paradigm (Colloca & Howick, 
2018). It is believed that the act of taking a placebo treatment triggers a pharmacological 
memory and therefore acts as a conditioned cue for a previously learned response of 
getting/feeling better (Colloca & Howick, 2018). More recently, expectancy theory is being 
explored as a mechanism, due to a patient having a conscious expectation that the treatment will 
make them feel better (Colloca & Howick, 2018). Evidence of how it can mediate placebos and 
their outcomes is with cases of anxiety (Turner, Deyo, Loeser, Von Korff & Fordyce, 1994). If a 
patient takes a placebo with the expectation that they will feel better, it can lead to a reduction in 
anxiety and an increase in immune system functionality (Turner et al., 1994). In situations 
involving pain, the expectation of pain relief can modulate the central regulation of pain through 
different bodily symptoms, such as the dopamine reward system and the endogenous opioid 
system (Price, Finniss & Benedetti, 2008). 
Emerging research suggests that the nature of the interaction between the practitioner and 
patient can also trigger the placebo effect (Jonas, 2011). The role practitioners play in 
administering medication is recognised as a key contributor to the health outcomes (Schaefer, 
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Sahin & Berstecher, 2018). This links back to expectancy theory where the expectation of a 
person feeling better can be enhanced by how effective a doctor’s performance is (Czerniak, et 
al., 2016). A meta-analysis looking into the influence of context effects on health outcomes found 
overall that practitioners who adopted a warm, friendly and reassuring manner are more effective 
than those who conduct more formal consultations due to greater placebo responding and the role 
that expectations play (Di Blasi, Harkness, Ernst, Georgiou & Kleijnen, 2001). However, this 
effect appears to apply only to patients who are susceptible to placebos (also known as placebo 
responders); the practitioner’s manner does not appear to affect people who are not susceptible to 
placebos (Czerniak et al., 2016).  
 
1.4 The use of placebos in clinical practice  
General practitioners (GPs) reportedly are the highest placebo prescribers (Hassan, Fauzi 
& Hasan, 2011). Underlying reasons offered surround the role that GPs play in health care. In 
Australia, general practitioners provide majority of medical primary health care, with 85% of 
Australians visiting their GP at least once a year (Gill, 2016). Furthermore, there is a wide range 
of medical conditions that general practitioners see compared to their specialist counterparts 
(Gill, 2016). Estimates put almost half of all GP consultations as not being possible to make a 
diagnosis that fits with the typical diagnostic criteria, due to the fleeting nature of symptoms 
(Gill, 2016). 
In a systematic review looking into placebo usage by general practitioners in clinical 
practice, twenty-two cross-sectional studies from twelve countries were analysed (Fassler, 
Meissner, Schneider & Linde, 2010). The review found placebo usage in clinical practice is not 
negligible, and that impure placebos are used more than pure placebos (Fassler et al., 2010). In 
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summary, impure placebos (also referred to as ‘active’ placebos) have pharmacological effects, 
however the effect on the disease at hand has not been proven, and is uncertain (Bishop, 
Aizlewood & Adams, 2014). This includes nutritional supplements advised or prescribed for 
patients who are not nutritionally deficient, or antibiotics prescribed for patients who have viral 
infections (Bishop et al., 2014). Pure placebos (also referred to as ‘inactive placebos’) have no 
pharmacological effects, two such examples being saline injections and sugar pills (Bishop et al., 
2014).  
In Germany, 45% of GPs surveyed used pure placebos compared to 76% who used 
impure placebos (Meissner, Hofner, Fassler & Linde, 2012). A similar study in the United 
Kingdom of 782 GPs found that 97% had used either kind of placebo at least once in their career, 
with as many as 77% of practitioners having used some sort of impure placebo at least once a 
week (Howick et al., 2013). The study also found gender effects; females were more likely to use 
placebos via positive suggestions and non-essential physical exams (Howick et al., 2013). An 
explanation offered was the number of days per week doctors spent in practice and number of 
patients they saw per week (Howick et al., 2013). They found in the sample that 92% of GPs 
working 0-3 days used non-essential physical exams frequently compared to 77% of participants 
who worked 5 days or more (Howick et al., 2013). As female doctors typically worked less days, 
hence seeing less patients, which may explain why they were more likely to use non-essential 
physical exams (Howick et al., 2013).  
The age of the general practitioner has also found to influence the frequency of placebo 
distribution. Younger GPs were significantly more likely to prescribe placebos compared to their 
older counterparts (Braga-Simoes, Soares Costa & Yaphe, 2015). However, these effects have 
not been replicated by other studies (Meissner et al., 2012). A study looking at orthopaedic 
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surgeons’ placebo usage found that years in practice influenced how likely they were to prescribe 
placebos (Baldwin, Wartolowska, & Carr, 2016). Trainee surgeons were more likely to prescribe 
placebos compared to more senior surgeons (Baldwin et al., 2016). However, it is unclear 
whether the likelihood to utilise placebo interventions is impacted by age, years of experience, or 
a mixture of both. As of yet, placebo usage by Australian GPs has not been researched.  
 
1.5 Attitudes towards placebos in clinical practice 
The clinical situation influences the likelihood of placebos being prescribed. 
Circumstances, in which placebos have reported being administered, include anxiety, pain, 
agitation, vertigo, sleep problems, asthma and withdrawal from recreational drugs (Nitzan & 
Lichtenberg, 2004). It is the general consensus amongst medical practitioners that in situations 
where there is a severe infection, fractures, cancers or any other biological failure, placebos 
shouldn’t be offered as a treatment option (Olesen, 2015). Rather, situations where placebos may 
be beneficial surround the alleviation of symptoms (Olesen, 2015). This is due to the nature of 
symptoms being quite complex and influenced by many factors such as cultural, social, and 
personal influences (Winkelman, 2010). In particular, social factors are able to modulate 
physiological and biological responses and alongside psychological processes, can influence 
multiple biological systems and affect the progression of a disease (Ader, 2007). The symptoms 
of the disease can be manifested into anxiousness, depression, dizziness, pain, nausea, and 
tiredness to name a few (Olesen, 2015). It is often believed by the medical literature that the 
placebo response differs according to the nature of the illness with most placebo responses being 
attributed to psychosomatic symptoms (Fent, Rosemann, Fassler, Senn & Huber, 2011). 
Moreover, they found that most GPs thought that placebos were ethically acceptable in certain 
OPEN-LABEL PLACEBO ATTITUDES  
7 
 
circumstances and would tell their patients that the intervention had helped other patients without 
specifically telling them it was a placebo (Howick et al, 2013). This is where the ethical lines 
become blurred and is often the course of many debates (Howick et al., 2013).  
Previously, it was a common thought amongst academics and practitioners that the main 
purpose of placebos was to distinguish between whether a patient’s symptoms were “real” or 
“fake” (Goodwin, Goodwin & Vogel, 1979). It is only quite recently that a growing number of 
practitioners report recognising that placebos might have therapeutic effects (Sherman & 
Hickner, 2008). In a study looking into the situational use of placebos, the authors found that 
practitioners used placebos as a supplement to main therapy (61%), a diagnostic tool (32%), to 
calm a patient (33%), to satisfy/ mollify a patient (23%), to control pain (23%) and instead of 
using medicine when using medicine is not justified (9%; Shah, Panchal, Vyas & Patel, 2009). 
The perceived mechanism of action has been described by practitioners as being mainly due to 
psychological mechanisms, however a combination of psychological and biochemical effects has 
been suggested, to a lesser degree (Nitzan & Lichtenberg, 2004). This is supported by other 
studies conducted with orthopaedic surgeons, where most believe that the placebo effect is due to 
psychological mechanisms, with a smaller number believing it is because of conditioning, natural 
history of disease and unexplained factors (Baldwin et al., 2016; Wartolowska, Beard & Carr, 
2014).  
Whilst there appears to be a role for placebos in healthcare due to the beneficial health 
outcomes associated with them, there are concerns as well. One concern regards the negative 
health outcomes, also known as ‘nocebo effects’ (Colloca, 2017). Nocebo effects are adverse 
events produced by negative expectations, compared to the positive expectations that trigger 
placebo effects (Colloca, 2017). Like the placebo effect, multiple factors such as the 
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psychosocial context and therapeutic environment on a patient’s mind, brain and body (for 
example negative information and prior unsuccessful therapies) can produce them (Colloca & 
Finniss, 2012). Doctors have reported concern with potential legal problems that could arise 
following the use of placebo interventions, if there were negative health outcomes (Baldwin et 
al., 2016; Wartolowska et al., 2014).  
Other concerns raised center around ethical use. One ethical issue is the endangerment of 
the doctor-patient relationship (Kisaalita, Roditi and Robinson, 2011). This is acknowledged 
across multiple studies where doctors have continually mentioned the risk of deterioration of the 
doctor-patient relationship (Baldwin et al., 2016; Wartolowska et al., 2014). In the study 
undertaken in the United Kingdom, they found that 90% of GPs agreed that placebos involving 
deception were unethical when they endangered the patient/doctor relationship (Howick et al., 
2013). When patient’s perspectives on placebo administration has been studied, it has been found 
that doctor approval is highly dependent on the deceptiveness of placebo administration 
(Kisaalita et al., 2011). To put quite simply, if a patient wants an effective treatment (commonly 
expecting a pharmacological treatment) yet receives a placebo instead, this can be seen as an 
unethical, violation of the patient’s right to be honestly and fully informed about treatment 
(Lichtenberg, Heresco-Levy & Nitzan, 2004). The study undertaken in the UK found majority of 
GPs stated that placebo interventions were unacceptable when they involved deception (Howick 
et al., 2013).  
 
1.6 Open-label placebos 
Open-label placebos have been offered as a way to mitigate some of the ethical and 
practicality issues that are currently found with traditional placebos, as they challenge the 
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widespread belief that placebos require deception in order to be effective (Kapthuck et al., 2010). 
The idea behind open-label placebos is patients are explicitly made aware they have been given a 
placebo hence eliminating the deception aspect (Carvalho et al, 2016). Early research shows 
disclosing to the patient that they are receiving a placebo does not necessarily diminish its 
effectiveness (Kisaalita et al., 2011). Moreover, having contextualised informed consent can 
reduce nocebo responses as it allows doctors to tailor the information about the possible 
treatment side effects to the patient (Wells & Kaptchuk, 2012). A study examining placebo 
interventions in practice from both the patients and practitioner’s perspective found that most 
patients were in support of placebo treatments, with 70% wanting to be informed that they were 
to be given a placebo (Fassler, Gnadinger, Rosemann & Biller-Andorno, 2011). This lends 
support from a patient’s perspective of open-label placebos.  
 
1.7 Clinical Trials into Open-Label Placebos 
While the practical use of open-label placebos is currently under-researched, the first 
experiment looking into placebos without deception can be backdated to 1965. In the 1965 
experiment, Park and Covi set out with the ‘paradoxical’ experiment by giving participants who 
suffered with anxiety, pills with no active medication in them. Although there was a low number 
of participants due to the nature of the trial, they found that patients had significant symptom 
improvement as well as the treatment rating highly by both the patients and practitioners (Park & 
Covi, 1965).   
It is only just recently that the idea of open-label placebos has come back into the 
literature, when Kaptchuck and colleagues undertook a small-randomized controlled trial. Their 
study included 80 Irritable Bowel Syndrome (IBS) sufferers who were given either open-label 
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placebo pills or no treatment controls (Kapthuck et al., 2010). They found there was a significant 
improvement in the group given the placebo compared to the group that had no treatment 
(Kapthuck et al., 2010). The main aim of their study was to challenge the notion that therapeutic 
use of placebos requires deceit and to remove the ethical conundrum that practitioners potentially 
face (Kapthuck et al., 2010). They were able to demonstrate that placebo effects can be 
harnessed without deception, thus coined the term ‘open-label placebo’.  
Further studies have aimed to replicate this effect in varying conditions and diseases. One 
such condition is chronic pain. Carvalho and colleagues (2016) tested 83 participants with 
ongoing chronic lower back pain. Participants were randomized into two groups; one who would 
receive the open-label placebo and the other group who would continue their current treatment 
(Carvalho et al., 2016). After 21 days, they found that open-label placebos had a statistically 
significant benefit over the treatment as usual group (Carvalho et al., 2016).   
More recently, open-label placebos have been suggested as a treatment option for cancer-
related fatigue. Traditionally, pharmacological treatments for cancer-related fatigue are only 
marginally effective or are not statistically significant compared to placebos, however still have 
sizeable side effects (Hoenemeyer, Kapthuck, Maheta & Fontaine, 2018). In a study comparing 
open-label placebos to ‘treatment as usual’ controls, it was found that open-label placebos 
corresponded with a significant improvement of roughly 29% on average in fatigue severity and 
a 39% improvement with fatigue-disruption on quality of life compared to the treatment as usual 
group (Hoenemeyer et al., 2018). Open-label placebos also had no reported adverse events or 
side effects (Hoenemeyer et al., 2018).  
The comparison between traditional placebos and open-label placebos has also been 
researched. In a study comparing the two analgesic placebos, they found that there was a 
OPEN-LABEL PLACEBO ATTITUDES  
11 
 
significant improvement between the two placebo groups and the control group, whereas there 
was not a significant difference between the two placebo groups (Mundt, Roditi & Robinson, 
2017). This lends support to the idea that placebos do not require deception in order to be 
effective.  
 
1.8 Current study 
Whilst there is emerging research surrounding the benefits of open-label placebos in the 
general population, the GPs’ role is still heavily under-researched. This study will build on 
current literature by looking at GPs’ perspectives, based on the fact that they are the most likely 
group to prescribe placebos compared to any other medical disciplines (Hassan et al., 2011). 
Therefore, the overall aim of this study is to investigate GPs’ attitudes towards open-label 
placebos in Australia. This will be firstly be addressed with the following research questions: 
1) Do general practitioners’ attitudes towards traditional placebos differ from their 
attitudes towards open-label placebos, and  
2) What are general practitioners’ attitudes regarding open-label placebo 
mechanisms and usage? 
Following on from the conclusions revealing gender differences in willingness to provide 
placebos in Howick’s (2013) study, it is hypothesised that:  
1) Women will be more willing to prescribe open-label placebos, compared to males, 
2) General practitioners seeing less patients per week will be  more willing  to 
prescribe an open-label placebo compared to those who see more patients per 
week, and  
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3) The gender difference in the likelihood to prescribe open-label placebos will be 
due to the number of patients seen per week.  
Moreover, in line with the past research conducted by Braga-Simoes (2015) and in other 
medical disciplines (Baldwin, et al., 2016; Wartolowska, et al., 2014), it is hypothesised that:  
4) Younger general practitioners will be more likely to prescribe open-label placebos 
compared to their older counterparts,  
5) General practitioners who have spent less years in practice will be more likely to 
prescribe open-label placebos, and  
6) This age difference in the likelihood to prescribe open-label placebos is due to the 
number of years in practice. 
Lastly, in order to inform future research, a last research question will address whether 
general practitioners’ have any concerns and additional comments regarding open-label placebos. 
 
Chapter 2 Method 
2.1 Participants 
The study consisted of General Practitioners in Australia (N= 54) with females (n = 35) 
and males (n = 19), aged 25 years or older. Participants were accrued between April and July 
2018 through two posts in the closed Facebook group ‘GPs Down Under’ (see reference for 
website URL) on the 17th of May 2018 and 23rd of June 2018. At the time, there were 5,604 
members in the group. Emails were also sent out via the Northern Health Network (formally 
known as Sonder as of July 2018; see reference for website URL), Home Doctor’s July 
newsletter (see reference for website URL), Australasian Association for Academic Primary Care 
(AAAPC), and randomly selected general practices in South Australia. Participants were 
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required to be fluent in English and to be active in general practice in Australia. Participation was 
voluntary and no incentive for participation was provided.  
 
2.2 Measures 
Participants were required to complete an on-line questionnaire for the study. The 
questionnaire was designed specifically for this study based on previously published surveys 
(Babel, 2013 Howick et al., 2013; Wartolowska et al., 2013) and was comprised of three different 
sections.   
The first part of the questionnaire collected participant demographics, including their age, 
gender, years practising, average number of patients seen per week, where they completed their 
basic medical degree, and their perceived culture. 
The second part of the questionnaire was designed to gather attitudes towards traditional 
placebos. As there has been some confusion surrounding what constitutes a placebo, the 
definition given was that a placebo is “any intervention or treatment, that objectively is known to 
have no specific effect, but for which a beneficial outcome occurs as a result of the patient 
believing in its efficacy” (Baldwin et al., 2016). The reason why the broad definition of a placebo 
was used, as opposed to breaking it down into pure and impure placebos like some other studies, 
was to keep it simplified, as the main focus of the study was to look at the attitudes towards 
open-label placebos. This definition also has had a high agreeance rate in the previous studies it 
has been used in (Baldwin et al., 2016; Hrobjartsson & Norup, 2003; Wartolowska, et al., 2013). 
Participants were then asked whether they agreed with the definition and to provide any 
additional comments they have.  
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Ten items were used to collect attitudes towards traditional placebos. The first two 
questions asked about their beliefs on the effectiveness of placebos and whether they can 
produce physical changes in the body, answered by a yes/no/don’t know response. The next four 
questions evaluated ethical attitudes, place in clinical practice, and likelihood to prescribe 
traditional placebos. The first three questions were rated on the same 5-point scale (strongly 
agree, agree, neither agree or disagree, disagree, and strongly disagree). The last question was 
rated on a different 5-point scale (highly likely, likely, unlikely, highly unlikely, and don’t know). 
The next two questions asked what the underlying mechanism/s and situational circumstances 
where participants were able to choose from a pre-set selection of answers (Baldwin et al., 2016). 
The last question was open-ended and asked what their concerns were with traditional placebos.  
The third part of the questionnaire introduced open-label placebos. Following a similar 
format to the second part of the questionnaire, participants were given a definition of an open-
label placebo; “Recent studies have shown that placebos can produce beneficial effects even 
when patients are told that they are receiving placebos. In other words, deception is not needed to 
achieve a therapeutic placebo response. This is referred to as an ‘open-label’ placebo”. Eight 
items were then used to gather attitudes towards open-label placebos. The first two questions 
asked was whether they think it can be effective and whether it can produce physical changes in 
the body. Like above, they had the option to respond yes/no/don’t know. The next three questions 
asked were ethics, place in clinical practice and likelihood to prescribe where they could answer 
on a 5-point scale in the first two questions (strongly agree, agree, neither agree or disagree, 
disagree, and strongly disagree), and the third (highly likely, likely, unlikely, highly unlikely, and 
don’t know). Participants were then asked what they thought the underlying mechanism/s is/are, 
broad situations where they would consider using, and groups of illness/conditions they would 
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consider using open-label placebos in. They could select from a pre-set range of responses and/or 
add their own additional comment. Participants were also asked to provide any additional 
concerns surrounding open-label placebos.  
 
2.3 Procedure 
Participants were invited to participate in the survey by accessing the survey website link 
via survey monkey. Prior to commencing the questionnaire, participants read the participation 
information sheet (Appendix 1) and provided inform consent (Appendix 2). Responses were 
entered directly into the online survey. Participants completed the online survey without any time 
constraints. The participants were advised that the survey would take between 15-20 minutes; 
however the average time taken was 7 minutes. Participants were given an option at the end to 
provide an email address if they wished to receive a summary of results.  
 
2.4 Ethical Considerations 
This study received approval from the University of Adelaide’s Human Research Ethics 
Committee. Confidentiality of participants were ensured to allow them to answer the 
questionnaire as honestly as possible. No participant names were linked with any of the 
completed questionnaires and participants were allowed to withdraw from the study at any point. 
 
2.5 Statistical Analyses 
Data was analysed using IBM SPSS Statistics, Version 22. Demographic data and 
comparative data for deceptive and open-label placebos was summarised using percentages to 
describe the responses to each question. When participants were allowed to choose more than 
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one answer to a particular question, the percentages did not add up to 100 and were therefore 
excluded. Two-way Analysis of Variances (ANOVA) with Tukey HSD post-hoc tests were used 
to explore the interaction of variables affecting the likelihood to prescribe open-label placebo 
treatment.  
Assumptions checked include searching for outliers on a scatterplot, using a histogram to 
make sure the outcome variable was normally distributed, and searching for missing data. 
Levene’s test for homogeneity of variance was used for the two-way ANOVAs. A p-value ≤ .05 
was considered significant. Effect sizes are reported alongside exact p-values. The cut-off scores 
for the effect sizes for Cohen’s d (d) are represented as 0.20 for small, 0.50 for moderate, and 
0.80 for large effects (Cohen, 1988).  
 
Chapter 3: Results 
 
3.1 Sample characteristics 
The sample characteristics can be found in Table 1. There were 54 participants who took 
part in the survey, with 41 complete responses (76% completion rate). The participants were 
mostly female, completed their basic medical degree in Australia, identified with Western 
culture, and saw between 51-100 patients per week. There appeared to be an even spread of ages, 










Sample characteristics of participants (N = 54) 
Category Count (%) 
Gender  
      Female 35 (65) 
      Male 19 (35) 
Age  
      25-39 19 (35) 
      40-54 21 (39) 
      55+ 14 (26) 
Years Practising  
Less than 10 years  23 (43) 
       10-19  12 (12) 
       20-29  10 (18) 
       30-40  7 (13) 
More than 40 years  2 (4) 
Patients a week  
Less than 25  10 (19) 
       25-50  11 (20) 
      51-100 22 (41) 
More than 100 11 (20) 
 
OPEN-LABEL PLACEBO ATTITUDES  
18 
 
3.2 Definition of placebo and placebo usage 
The majority of participants (n = 45, 88%) agreed with the provided definition of 
placebo. Six Participants disagreed with the definition of placebos and offered additional 
comments, such as: the patient did not necessarily have to believe in it (n = 3), the doctor’s role 
needs to be included (n = 1), and placebo effects are objective and measurable (n = 1). One 
participant believed that every treatment (including those of a pharmacological nature) has a 
degree of placebo response, so the definition was incomplete (n = 1). The frequency that 
Participants have prescribed or suggested a traditional placebo can be found in Table 2.  
 
Table 2 





Never 17 (33) 
Rarely (<1 per year) 12 (24) 
Occasionally (>1 per year) 13 (25) 
Often (>1 per month) 4 (8) 
Frequently (<1 per week) 5 (10) 
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3.3 Do General Practitioners’ attitudes towards traditional placebos differ from their 
attitudes towards open-label placebos? 
Participants were asked to answer identical statements surrounding their beliefs towards 
traditional placebos and then again with open label placebos as shown in Figure 1. All but one 
participant believed that traditional placebos can be effective (n = 50, 98%) with most believing 
they can produce physical changes in the body (n=36, 72%). This is compared to around half of 
participants believing open-label placebos can be effective (n = 29, 55%) and can produce 
physical changes in the body (n = 22, 45%). Whilst ‘yes’ responses varied depending on the 
question, ‘no’ responses remained fairly equal across both placebo interventions and the 
questions. For open-label placebos, where ‘yes’ responses decreased, ‘I don’t know’ responses 
increased. Most participants believed that traditional placebos have a place in clinical practice (n 
= 37, 73%) whereas half believed the same with open label placebos (n = 27, 54%). Roughly the 
same number of participants would prescribe both traditional placebos (n = 28, 55%) and open-
label placebos to an adult (n = 26, 52%). Just over half of participants believed that traditional 
placebos can be delivered ethically (n = 31, 61%) compared to open-label placebos (n = 37, 
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3.4 Attitudes regarding open-label placebo mechanisms and usage 
For attitudes regarding open-label placebo mechanism and situational use, percentages 
were not provided, as participants were allowed to select more than one response (refer to Table 
3). The majority of participants reported that the mechanism behind the open-label placebo effect 
are because of psychological reasons such as expectations, the patient/doctor relationship, or the 
natural course of the disease. In relation to situational context, majority of participants believed it 
to be a suitable treatment for non-specific symptoms, to control pain, and when all other 
therapies have been exhausted. The groups of illness/diseases that the participants indicated they 
would consider using an open-label placebo was mainly for sleep issues, physical symptoms 
such as pain, itchiness and excessive sweating and mood disorders such as anxiety, depression 
and panic attacks. 
 Participants were also given the opportunity to add any additional comments. The six 
comments given were in relation to using open-label placebos for psychological disorders, 
somatisation, fixed issues, self-limiting diseases, and any complex problem for which trial and 
review of treatment is an appropriate course guided by the patient’s values and beliefs. Two 
participants said there were no situations in which they would consider using an open-label 











Attitudes regarding the mechanisms and situations with open-label placebos 
 
Question N Count 
In your opinion, what is the mechanism behind 
the open-label placebo effect?  
47  
       Psychological/Expectations  38  
       Patient/doctor relationship  37  
       The natural course of the illness  32 
       Conditioning  15 
       Physiological  12 
       Positive energies  1 
       Unexplained factors  19 
       Other   4 
Would you ever consider the use of an open-label 
placebo in these situations?  
41  
       As a diagnostic tool  11  
       When all other therapies have been 
exhausted 
 23  
       As a treatment for a non-specific symptom  33  
       To calm or mollify a complaining patient  18  
       To control pain  25  
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Would you ever consider the use of an open-label 
placebo for these groups of illnesses/disease?  
42  
       Physical illnesses (i.e. hypertension, cancer 
etc.) 
 8 
       Physical symptoms (i.e. pain, itchiness and                                            
excessive sweating etc.) 
33 
       Mood disorders (i.e. anxiety, depression, panic 
attacks etc.) 
 28 
       Sleep issues  37 
       Other  11 
 
3.5 The influence of demographic variables on the likelihood to prescribe open-label 
placebos 
The first three hypotheses predicted that women will be more likely to prescribe open-
label placebos compared to males due to seeing less patients per week. Participants were divided 
into 2 groups according to their gender (Group 1: Female; Group 2: Male). Participants were also 
divided into four groups according to the number of patients seen per week (Group 1: less than 
25; Group 2: 25-50; Group 3: 51-100; Group 4: more than 100). The results from a two-way 
ANOVA showed the interaction effect between gender and patients seen per week was not 
statistically significant, F(3,42) = 1.60, p = .20 and had a small effect size (partial eta squared 
= .10). The main effect for gender showed that females were more likey to prescribe an open-
label placebo than males but this did not reach statistical significance, F(1,42) = 0.55, p = .46 
and had a small effect size (partial eta squared = .01). The main effect for patients seen per week 
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was also not statistically significant, F(3,42) = 0.83, p = .47 and had a small effect size (partial 
eta squared = .06).  
 





The last three hypotheses predicted that younger practitioners will be more likely to 
prescribe open-label placebos compared to males due to spending less years in practice. 
Participants were divided into three groups depending on their age (Group 1: 25-39; Group 2: 
40-54; Group 3: 55+). Participants were also divided into five groups depending on how many 
years they have been practising (Group 1: less than 10; Group 2: 10-19; Group 3: 20-29; Group 
4: 30-40; Group 5: more than 40). The results from a two-way ANOVA showed the interaction 
effect between age and years practicing was not statistically significant, F(2,41) = 1.39, p = .26 
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and there was a small effect size (partial eta squared = .06). There was a statistical significant 
result for years practising, F(4,41) = 2.95, p = .03; however the effect size was small (partial eta 
squared = .22. Further post-hoc comparisons using the Tukey HSD indicated that the mean score 
of the different groups was not statistically significant. The main effect for age was not 
statistically significant, F(2,41) = 0.02, p = .98 and there was no effect size (partial eta squared 
= .01).  
 








3.6 General practitioners’ concerns and comments regarding open-label placebos. 
Throughout the survey, thirty-three participants left comments regarding additional 
comments or concerns regarding open-label placebos. Most additional concerns regarding open-
label placebos centred on the patient’s perspective (n = 10). These comments ranged from patient 
acceptability (n = 3) informed consent (n = 3), patients’ expectations (n = 1) and patients 
misunderstanding of what an open-label placebo (n = 1). Two participants believed that the only 
way placebos work is if the patient still believes that it is efficacious and not “inert”, hence a 
traditional placebo. Secondly, concerns around the lack of efficacy and research in clinical 
practice were raised (n = 6), with one participant believing they have a lack of experience in this 
area (n = 1). They went on to say they were worried it may get in the way of “proper” 
investigation and treatment, which was echoed by another participant (n = 1). Moreover, it was 
commented that open-label placebos should be used only when delay in successful treatment 
would not be a problem (n = 2). Furthermore, participants (n = 2) believed that the open-label 
placebo still requires deception and one participant worried about potential litigation if it does 
not work.  
There were a few positive comments made by participants towards open-label placebos 
(n = 7). These include embracing open-label placebos due to reasons such as the benefits only 
marginally outweighing the risks for some pharmacological medications (n = 1), realisation that 
they use placebo therapy already in other forms (n = 2), and there are certain situations, such as 
those on opiates and benzodiazapam, that they believe open-label placebos could be beneficial 
for (n = 1).  
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Chapter 4: Discussion 
4.1 Overview of study 
The purpose of this study was to investigate general practitioners’ attitudes towards open-
label placebos. More specifically, this study aimed to explore attitudes between traditional and 
open-label placebos, perceived underlying mechanisms, situational usage, demographic 
influences on the likelihood to prescribe, and additional concerns and comments with open-label 
placebos.  
 
4.2 Definition and frequency of use of placebo interventions in clinical practice 
In the present study, 88% of participants agreed with the definition of placebo provided. 
This result is consistent with other studies using the same, or similar, definition of placebo 
(Baldwin, et al., 2016; Babel, 2013; Hrobjartsson & Norup, 2003). One participant who 
disagreed with the definition stated that the patient and treating doctor needed to be included in 
the definition. This foreshadows the belief that a strong underlying mechanism is the 
patient/doctor relationship.  
 Sixty-seven percent of general practitioners surveyed had prescribed or suggested 
a placebo intervention in their career. This result is lower than reported in other countries such as 
the United Kingdom (97%), Germany (88%), Denmark (86%), and Poland (80%) (Babel, 2013; 
Howick et al., 2013; Hrobjartsson & Norup, 2003; Meissner et al., 2012). However, this is higher 
than reported in the United States (56%; Kermen et al., 2010). A reason for this difference could 
be the geographical location and subsequent health care systems, medical education and culture. 
Another difference is United States does not have ‘General Practitioners’, rather ‘Primary Care 
Physicians’ (National Center for Health Statistics, 2018). These two terms are not synonymous, 
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therefore indicating the different roles they play, which may account for some of the difference in 
results (National Center for Health Statistics, 2018). Moreover, differences could have resulted 
from the wording of questions between the studies. In the United Kingdom, placebo 
interventions were separated into pure and impure placebos, with specific examples given, such 
as positive suggestions, non-essential physical exams and sugar pills (Howick et al., 2013). The 
study undertaken in Poland did not refer to placebos explicitly, rather identified them as non-
specific methods (Babel, 2013). Perhaps if the current research followed the same format of 
either of these studies, results reported of placebo prescription may have been higher. In addition, 
the present study examined placebo prescription over shorter periods (e.g. at least once a week, 
once a month, once a year etc.) whereas the Danish and United States studies conducted longer 
periods of examination/observation (e.g. how many times per year do you placebo placebos?) 
(Hrobjartsson & Norup, 2003; Kermen et al., 2010). 
 
4.3 Research Question 1: Differences between Traditional and Open-Label Placebos 
The first research question intended to examine whether general practitioners’ attitudes 
towards traditional placebos and open-label placebos differed. This was included because there 
does not appear to be any research on Australian GPs’ attitudes towards placebo interventions. 
Asking questions surrounding traditional placebos allowed a solid comparative basis for attitudes 
towards open-label placebos, with an aim to pinpoint any differences. A major/ pattern within the 
results was that ‘no’ responses by participants appeared to be evenly spread between traditional 
placebos and open-label placebos. This indicated that participants were against placebo 
interventions collectively and the open-label aspect did not affect their feelings. Participants’ 
reasons given in subsequent comments included interventions involving deception and their 
OPEN-LABEL PLACEBO ATTITUDES  
29 
 
disbelief that placebo interventions work. The number of ‘no’ responses were low for the first 
three questions regarding the placebo effect and clinical practice (n ≥ 6), however, responses 
quadrupled for whether they would prescribe the intervention to an adult (n = 20). This shows 
they are rather accepting of the placebo in clinical practice, although are hesitant to use it 
themselves. Reasons for this are discussed below. 
Another major finding was that the number of ‘don’t know’ responses increased with 
open-label placebos. This highlights that GPs are not against open-label placebos, although 
indicates that they are unsure of the practicality. This is reflective of the limited research 
conducted in the area (Charlesworth et al., 2017). Lastly, the number of ‘yes’ responses from 
traditional placebos to open-label placebos decreased, particularly for the first three questions. 
This represents the shift to ‘don’t know’ responses, and the gap in the literature.  
The last question regarding whether the intervention can be delivered ethically was the 
only question where answers for open-label placebos did not follow the above trends. As such, 
‘yes’ responses were higher, and ‘no’ and ‘don’t know’ responses were lower. This is significant 
as one of the biggest concerns previously raised around placebo interventions were the ethical 
implications, in particular traditional placebos involving deception (Kisaalita et al., 2011). By 
removing the deceptive aspect, 72% of participants believed placebos can be delivered ethically 
(up from 60%), and only a small number believing they cannot (6%). This result highlights that 
open-label placebos are a viable treatment option pending further research, due to the decreased 
ethical implications that has occurred due to the removal of deceit.  
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4.4 Research Question 2: Underlying mechanisms and usage 
The second research question evaluated the perceived mechanisms and situational usage 
of open-label placebos. The majority of GPs surveyed believed the underlying mechanisms are 
(1) psychological reasons/expectations, (2) the patient/doctor relationship, and/or (3) the natural 
course of disease. The first mechanism, psychological reasons/expectations, aligns with past 
findings from studies conducted in Poland, Denmark, and the United States (Babel, 2013; 
Hrobjartsson & Norup, 2003; Kermen, et al., 2010). Therefore, it echoes the emergence of 
Expectancy Theory being part of the explanation behind placebos (Colloca & Howick, 2018). 
The mechanism of the patient/doctor relationship was a close second among GPs. This shows 
that GPs are aware of how their interaction with a patient in consultations can elicit certain health 
outcomes (Schaefer, et al., 2018). Therefore, GPs should be involved in the creation of strategies 
to implement open-label placebos in clinical practice, in a manner that avoids deception and 
maximises health outcomes. The third proposed mechanism, natural course of the illness, 
provides insight into the nature of general practice and circumstances involving placebo 
interventions. GP’s often address a range of fleeting symptoms,  thus placebo efficacy increases 
as patients’ symptoms are alleviated over the natural course of the illness. However, they 
attribute this to the prescribed placebo by prescribing placebo interventions, resulting in a belief 
by the patient that it has ‘worked’ (Gill, 2016). For example, prescribing antibiotics to a patient 
that has a cold (Kenealy & Arroll, 2013). The patient will likely recover on his or her own due to 
the natural course of illness, rather than the effects of the antibiotics (Kenealy & Arroll, 2013). 
However, when antibiotics are taken, there is the risk of side effects and antibiotic resistance 
bacteria (Kenealy & Arroll, 2013). Potentially, GP’s could instead prescribe open-label placebos, 
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which would trigger the placebo effect with the benefit of decreasing the side effects, associated 
with pharmacological treatment.  
Furthermore, common situational contexts that participants would use open-label 
placebos are for (1) non-specific symptoms, (2) when all other therapies have been exhausted, 
and (3) to control pain. This contradicts Goodwin’s (1979) study that argued the majority of 
doctors used placebos to determine whether patients were exhibiting real or exaggerated 
symptoms. This reflects the shift in views of modern medicine towards support for the mind-
body connection (Sherman & Hickener, 2008). Due to the nature of general practice, the first 
preference of non-specific symptoms were to be expected (Gill, 2016). Secondly, GPs utilising 
placebo treatments when all other therapies have been exhausted could be due to the trial and 
error process that GPs endure in the treatment of conditions and symptoms (Le Roux, Powell, 
Banks & Ridd, 2018). Respondents’ third selection, controlling pain, is no surprise considering it 
is one of the most common areas researched relating to the placebo effect, and has demonstrated 
extensive success (Kisaalita et al., 2014). 
The most common group of conditions/illnesses were (1) physical symptoms, (2) sleep 
issues and (3) mood disorders. A reason why physical symptoms (such as pain, itchiness, and 
excessive sweating) was selected could be due to prevalent ongoing current pharmacological 
treatment, and as a result, having accumulative and therefore more serious side effects (Ward et 
al., 2010; Turner & Connolly, 2018). Instead, open-label placebos can greatly reduce side effects. 
Treatment for sleep issues and mood disorders (such as the case of mild-moderate depression) 
have been reported in the literature as having no significant difference to placebo interventions 
(Kirsch, et al., 2008; Yeung et al., 2018). As a result, it is heavily debated whether condition 
improvement from these medications is due to the pharmacological treatment itself or the 
OPEN-LABEL PLACEBO ATTITUDES  
32 
 
placebo effect (Kirsch, et al., 2008; Yeung et al., 2018). Unlike placebo interventions, 
medications for sleep issues and mood disorders have a higher risk of side effects (e.g. addiction, 
nausea, drowsiness etc.; Kirsch, et al., 2008; Yeung et al., 2018). Additionally, they are expensive 
for the patient and the Australian Government (Fox, 2003). Open-label placebo interventions 
have the potential to be an effective substitute treatment, which would also eliminate some of the 
more serious side effects and costs associated with pharmacological treatment. Moreover, these 
findings may be applicable to the creation and future implementation of open-label placebos in 
clinical practice, by creating condition-specific or complaint-specific open-label placebos based 
on the aforementioned areas. 
 
4.5 Hypotheses 1 – 6: Demographic influences on the likelihood to prescribe placebos 
Results from the current study did not support the first hypothesis that females were more 
likely to prescribe open-label placebos compared to males. This did not align with the the United 
Kingdom study where female GPs were more likely to prescribe placebos (Howick et al., 2013). 
This could be due to findings that women were more likely to use positive suggestions and non-
physical exams, which were specifically mentioned in the survey, whereas the present study only 
referred to the broad definition. Additionally, as the present survey was emailed out to academic 
GPs (AAAPC), this could be an explanation for why there were not gender effects. This is 
consistent with a previous study (Sherman & Hickener, 2008).  
The second hypothesis was GPs who saw less patients per week would be more likely to 
prescribe open-label placebos, which was based on previous findings (Howick et al., 2013). This 
hypothesis was not supported by the current study. In fact, further research could indicate that the 
opposite is true; more patients seen per week can lead to additional placebo prescribing. This is 
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because GPs in the United Kingdom, Germany, and Poland studies saw on average 123, 250, and 
140 patients per week respectively, and had a higher rate of placebo prescriptions (Babel, 2013; 
Howick et al., 2013, Meissner et al., 2012 ). This differs to the present findings in which only 
20% of participants saw more than 100 patients per week. 
The third hypothesis was based on Howick’s (2013) proposal that the gender difference 
in placebo prescription rates could be a result of the number of days worked and consequently 
the number of patients seen per week. However, the present study did not find support for this. 
This could be due to the above reasons such as the lack of gender difference and patients seen 
per week.  
The fourth hypothesis was that younger GPs would be more likely to prescribe open-label 
placebos compared to older general practitioners. This study showed that this result is not 
significant. Therefore, this does not support the results of previous research by Braga-Simoes 
(2015), who found younger general practitioners were more likely to prescribe placebos 
compared to their older counterparts. However, it does support other studies, which did not find 
an age difference (Meissner et al., 2012). 
 The fifth hypothesis was that years in practice would affect the likelihood of prescribing 
open-label placebos. These results were based on findings from Wartolowska (2014) and 
Baldwin (2016) who found that younger trainee orthopaedic surgeons were more likely to be 
supportive of placebo interventions compared to older senior orthopaedic surgeons. The results 
of the present study did not support their findings. Whilst a significant result was found in the 
two-way ANOVA, further post-hoc tests failed to find a significant difference between the 
groups. This means that there may be an effect here, however due to the small sample size 
(N=54) and lack of statistical power, it was not picked up. Future research with larger sample 
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sizes would benefit from investigating this further to see if it influences influence on the 
likelihood to prescribe open-label placebos.  
The results of a two-way ANOVA did not support the sixth hypothesis regarding younger 
general practitioners being more likely to prescribe open-label placebos due to having spent less 
years in practice. Reasons for this could include the lack of significant results, as well as the 
study being underpowered and therefore potentially not reflective of the target population. 
 
4.6 Research Question 4: Additional concerns and comments with open-label placebos  
The last research question related to any additional concerns or comments GPs have 
around open-label placebos. One of the two most common concerns/comments reported was the 
importance of considering the open-label placebo from the patient’s perspective. Comments 
regarding the patient’s perspective included how accepting patients will be to open-label 
placebos, whether the patient will be able to give informed consent, and the potential 
misunderstanding of what an open-label placebo is.. These concerns from the patient’s 
perspective, particularly with patient acceptability, is not novel with placebo interventions. As 
such, in a study examining the difference between GP and patient views towards traditional 
placebos, GPS underestimated how accepting patients would be to placebo interventions (Lynoe, 
Mattsson & Sandlund, 1993). A reason for this difference could be that the perception of 
prescribing a placebo intervention represents a socially undesirable behaviour due to negative 
ethical implications GPs may perceive. The second major concern/comment related to the lack of 
research into, and thus the lack of efficacy of, placebos. Once again, these comments are 
reflective of the current limited literature on open-label placebos (Charlesworth et al., 2017). 
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Further research is required to determine the efficacy of open-label placebos for a variety of 
conditions/illnesses.  
 
4.7 Strengths and Limitations  
A clear strength of this study is that it is the first to investigate medical practitioners’ 
attitudes towards open-label placebos. This study specifically sampled GPs as they are an 
important stakeholder with placebo interventions due to reportedly being the highest placebos 
prescribers (Hassan et al., 2011). Therefore, understanding their current attitudes provides 
direction towards future research. This study is also a first in exploring attitudes towards 
traditional placebo interventions in Australia, therefore providing insight into the current 
behaviours in general practice. Questions administered enabled GPs to reflect on their own 
placebo prescribing behaviours and engage them in the placebo literature. Additionally, the items 
used to measure attitudes towards placebo interventions were adapted from previous 
experimental research, adding to the validity and reliability of these measures for future research 
into placebo interventions. Unlike previous studies, the present study provided open-ended 
questions, allowing participants to freely respond. This allowed deeper examination of the 
nuances of participants’ beliefs regarding placebo intervention (Braun and  
Clarke, 2013) 
 Results from this study have contributed to existing knowledge in the current placebo 
literature and creates a platform for the direction of future research. 
Despite these notable strengths, the present study was not without limitations. The main 
limitation of this study was the sample size. Reasons as to why there was the small sample size 
included it being a homogenous group (GPs in Australia). GPs, particularly compared to other 
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medical disciplines, typically have low survey response rates, as studies have found their 
responses have steadily declined for the past decade (Templeton, 1997; Cunningham, et al., 
2015). GPs who declined to take part in the current survey provided  reasons, such as inundation 
of surveys and not enough time. This echoes the previous finding that general practitioners’ have 
reported survey burden, high volume of survey requests, the length of the questionnaire, 
insufficient background information, and the perceived value of the research as being reasons as 
to why there are low response rates (Cunningham, et al., 2015; Morris, Cantril & Weiss, 2001). 
Other factors include the location of the general practitioner, originating institution, being too 
busy to complete research, and being less qualified (Fielding, Clothier, Stocks & Kelly, 2005). 
Similarly, some medical practices have an office policy regarding participation in surveys 
(Wiebe, Kaczorowski & MacKay, 2012). In addition, the lack of incentive likely also affected the 
response rate. In a previous study, Gps who were offered a financial incentive were more likely 
to participate in surveys compared to those who were not (Crouch, Robinson & Pitts, 2011; 
Cunningham, et al., 2015).  
Additionally, the use of a generalised, online survey tool could have also influenced the 
number of results. Online survey tools have the poorest response rate compared to other survey 
tools (e.g. postal surveys and telephone surveys), particularly when a personalised nature of 
recruitment is not used (Crouch et al., 2011).  
Moreover, the data may not be representative of the whole population, as the sample 
gender distribution did not match the gender distribution of GPs in Australia. There is a roughly 
even split of registered male and female GPs in Australia (Medical Board of Australia, 2018), 
which is starkly different to the current survey where more women responded compared to males 
(65% vs. 35% respectively). This is in line with the current literature, which shows that it is 
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easier to recruit female participants for surveys and interviews in general compared to males 
(Slauson-Blevins & Johnson, 2016).  
Another limitation is that the present study used self-report measure. There involves the 
risk that participants have been influenced by recall bias where there could be an 
underestimation/overestimation of answers to certain questions. Moreover, there was the delicate 
nature of the topic. As placebos are a grey area in modern medicine with strong ethical 
implications, general practitioners’ may be wary about admitting support for placebo 
interventions, and whether they have prescribed a placebo in the past and/or the likelihood to 
prescribe an open-label placebo in the future The advertisement of the survey was included in the 
group (AAAPC). This group is for academic general practitioners’ and therefore may prime 
some responses to be in support of open-label placebos due to them having an interest in research 
themselves, which could result in a sampling bias in the present study.  
 
4.8 Future research  
Future research should therefore look at overcoming the above limitations. Replication 
studies are needed to examine demographic influences using a more representative sample. 
Improvement to recruitment methods should look at including postal surveys, more personalised 
methods, and incentives in an attempt to increase participant response. This should allow the 
capturing of more perspectives and highlight any demographic factors that influence the 
likelihood to prescribe open-label placebos.  
Further research into clinical trials with open-label placebos should use experimental 
conditions that involve physical symptoms (such as pain, itchiness, and excessive sweating), 
sleep issues, and mood disorders (such as depression, anxiety, and panic attacks) as reflected by 
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the commonly chosen areas by general practitioners. How general practitioners, amongst other 
medical professionals, can deliver the open-label placebo to both reduce deception and increase 
health outcomes also needs to be researched in further detail. More in-depth research looking at 
placebo usage in Australia can look at the different types of placebos used (e.g. impure vs pure) 
in a similar format to the other studies undertaken in the United Kingdom and Poland. This 
would lead to a deeper understanding of placebo-prescribing behaviours that the present study 
missed due to it not being a prime focus of this study. Overall, future research in this area can 
lead to rewarding outcomes and open-label placebos have the potential to become a successful 
treatment option.   
 
Chapter 5: Conclusions 
The current study provides meaningful insight into the currently under-researched area of 
open-label placebos. The study revealed that general practitioners’ attitudes towards traditional 
placebos, compared to open-label placebos, only differed for those who were accepting of 
placebo interventions in the first place. The findings of the study showed strong support for 
psychological factors, such as expectations, and the patient/doctor relationship as the underlying 
mechanisms behind the open-label placebo effect. Additionally, this study suggests that 
Australian general practitioners would use open-label placebos in cases of non-specific or 
physical symptoms, which provides a valuable starting point in developing and implementing 
open-label placebos in clinical practice. Although no demographic influencers were found in the 
likelihood to prescribe open-label placebos, future research with larger samples could evaluate 
this further. These findings highlight concerns around the lack of research in this area and how 
OPEN-LABEL PLACEBO ATTITUDES  
39 
 
open-label placebos can be offered to a patient. Therefore, further research is necessary in both 
clinical trials and practice, to address these concerns.  
Overall, as the cost and side effects of pharmacological treatment increases, open-label 








Ader, R. (2007). Psychoneuroimmunology (4th ed.). Amsterdam: Elsevier/Academic Press. 
Babel, P. (2013). Use of placebo interventions in Primary Care in Poland. Medical Principles 
and Practice, 22(5). 484-488. doi:  10.1159/000351563 
Baldwin, M. J., Wartolowska, K., & Carr, A. J. (2016). A survey on beliefs and attitudes of 
trainee surgeons towards placebo. BMC Surgery, 16(7), doi:  10.1186/s12893-016-0142-5 
Bishop, F. L., Aizlewood, L., & Adams, A. E. M. (2014). When and why placebo-prescribing 
is acceptable and unacceptable: A focus group study of patients’ views. PLoS ONE, 9(7). doi: 
10.1371/journal.pone.0101822 
Braga-Simoes, J., Costa, P. S., & Yaphe, J. (2017). Placebo prescription and empathy of the 
physician: A cross-sectional study. European Journal of General Practice, 23(1), 98-104. 
doi:  10.1080/13814788.2017.1291625 
Braun, V., & Clarke, V. (2013). Successful qualitative research: A practical guide for 
beginners. London: Sage 
Carvalho, C., Caetano, J. M., Cunha, L., Rebouta, P., Kaptchuk, T. J. & Kirsch, I. (2016). 
Open-label placebo treatment in chronic low back pain: a randomized controlled trail. PAIN, 
157(12). doi: 10.1097/j.pain.0000000000000700 
Chaplin, S. (2006, March 5). The placebo response: an important part of treatment. 
Prescriber. Retrieved from https://onlinelibrary.wiley.com/doi/pdf/10.1002/psb.344 
Charlesworth, J. E. G., Pekovic, G., Kelley, J. M., Hunter, M., Onakpoya, I., Roberts, N., 
Miller, F. G., & Howick, J. (2017). Effects of placebos without deception compared with no 
treatment: a systematic review and meta-analysis. Journal of Evidence-Based Medicine. doi: 
10.1111/jebm.12251 




Chen, X., Zou, K., Abdullah, N., Whiteside, N., Sarmanova, A., Doherty, M., & Zhang, W. 
(2017). The placebo effect and its determinants in fibromyalgia: meta-analysis of randomised 
controlled trials. Clinical Rheumatology, 36(7). 1623-1630. doi:  10.1007/s10067-017-3595-8 
Cho, H. J., Hotopf, M., & Wessely, S. (2005). The placebo response in the treatment of 
chronic fatigue syndrome: a systematic review and meta-analysis. Psychosomatic Medicine, 
67(2), 301-313. doi: 10.1097/01.psy.0000156969.76986.e0 
Cohen, J. (1988), Statistical Power Analysis for the Behavioral Sciences, 2nd Edition. 
Hillsdale, N.J.: Lawrence Erlbaum. 
Colloca, L. (2017). Nocebo effects can make you feel pain. Science, 358(6359), doi: 
10.1126/science.aap8488 
Colloca, L., & Finniss, D. (2012). Nocebo effects, patient-clinician communication, and 
therapeutic outcomes. JAMA, 307(6). doi:10.1001/jama.2012.115 
Colloca, L., & Howick, J. (2018). Placebos without deception: outcomes, mechanisms and 
ethics. International Review of Neurobiology, 138, 219-240. doi: 10.1016/bs.irn.2018.01.005 
Crouch, S., Robinson, P., & Pitts, M. (2011). A comparison of general practitioner response 
rates to electronic and postal surveys in the setting of the National STI prevention Program. 
Australian and New Zealand Journal of Public Health, 35(2). 
Cunningham, C. T., Quan, H., Hemmelgarn, B., Noseworthy T., Beck, C. A., Dixon, E., 
Samule, S., Ghali, W. A., Sykes, L. L., & Jette, N. (2015). Exploring phsycian specifalist 
response rates to web-based surveys. BMC Medical Research, 15. doi:  10.1186/s12874-015-
0016-z 
OPEN-LABEL PLACEBO ATTITUDES  
42 
 
Czerniak, E., Biegon, A., Ziv, A., Karniele-Miller, O., Weisser, M., Alon, U., & Citron, A. 
(2016). Manipulating the placebo response in experimental pain by altering doctor’s performance 
style. Frontiers in Psychology, 7. doi:  10.3389/fpsyg.2016.00874 
De Dyn, P. P., & D’Hooge, R. (1996). Placebos in clinical practice and research. Journal of 
Medical Ethics, 22. doi: 10.1136/jme.22.3.140 
Department of Health, Australian Government. (2017, December 20). Expenditure and 
Prescription Report 2016-2017. Retrieved from 
http://www.pbs.gov.au/info/statistics/expenditure-prescriptions-twelve-months-to-30-june-2017 
Di Blasi, Z., Harkness, E., Ernst, E., Georgiou, A., & Kleijnen, J. (2001). Influence of 
context effects on health outcomes: a systematic review. Lancet, 10(357), 757-762. 
Fassler, M., Gnadinger, M., Rosemann, T., & Biller-Andorno, N. (2011). Placebo 
interventions in practice: a questionnaire survey on the attitudes of patients and physicians. 
British Journal of General Practice, 61(583), 101-107.  https://doi-
org.proxy.library.adelaide.edu.au/10.3399/bjgp11X556209 
Fassler, M., Meissner, K., Schneider, A., & Linde, K. (2010). Frequency and circumstances 
of placebo use in clinical practice – a systematic review of empirical studies. BMC Medicine, 8. 
doi:  10.1186/1741-7015-8-15 
Fent, R., Rosemann, T., Fassler, M., Senn, O., & Huber, C. A. (2011). The use of pure and 
impure placebo interventions in primary care – a qualitative approach. Family Practice, 12(11). 
doi: 10.1186/1471-2296-12-11. 
Fielding, J., Clothier, H., Stocks, N., & Kelly, H. (2015). What factors facilitate a GP survey 
high response rate? Australian Family Physician, 34(10). 
OPEN-LABEL PLACEBO ATTITUDES  
43 
 
Fox, P. D. (2003). Prescription drug benefits: cost management issues for medicare. 
Medicare & Medicaid Research Preview, 25(2). 
Gill, G. (2016, July 11). Australian GPs are offered guidelines not relevant to their patients 
and they often ignore them. Retrieved from http://theconversation.com/australian-gps-are-
offered-guidelines-not-relevant-to-their-patients-and-they-often-ignore-them-62168 
Goodwin, J. S., Goodwin, J. M., & Vogel, A. V. (1979). Knowledge and use of placebos by 
house officers and nurses. Annals International Medicine, 91(1), 106-110 
‘GPs Down Under’ Facebook group. Retrieved from 
https://www.facebook.com/groups/gpsdownunder/ 
Hassan, T., Fauzi, M., & Hasan, D. (2011). Perceptions of placebo therapy among health 
practitioners in Jazan Region of Saudia Arabia. International Journal of Health Sciences, 5(1), 
45-49. 
Home Doctor Website. Retrieved from https://homedoctor.com.au 
Hoenemeyer, T. W., Kaptchuk, T. J., Mehta, T. S., & Fontaine, K. R. (2018). Open-label 
placebo treatments for cancer-related fatigue: A randomized-controlled clinical trial. Scientific 
Reports, 8(1). doi: 10.1038/s41598-018-20993-y 
Howick, J., Bishop, F. L., Heneghan, C., Wolstenholme, J., Stevens, S., Hobbs, F. D. R., & 
Lewith, G. (2013). Placebo use in the United Kingdom: Results from a national survey of 
primary care practitioners. PLoS ONE, (8), 3. doi:10.1371/journal.pone.0058247 
Howick, J., Friedemann, C., Tsakok, M., Watson, R., Tsakok, T., Thomas, J., Perera, R., 
Felming, S., & Heneghan, C. (2013). Are treatments more effective than placebos? A systematic 
review and meta-analysis. PLoS One, 8(5). doi:  10.1371/journal.pone.0062599 
OPEN-LABEL PLACEBO ATTITUDES  
44 
 
Hrobjartsson, A., & Norup, M. (2003). The use of placebo interventions in medical practice – 
a national questionnaire survey of Danish clinicians. Evaluation & the Health Professions, 26(2). 
153-165. doi: 10.1177/0163278703026002002 
Jara, V. E. (2014). Ritual and Healing: Explorations of the placebo phenomenon and 
Peruvian curanderismo in Iquitos, Peru (Unpublsihed doctoral dissertation). New College of 
Florida, Saratosa, Florida.  
Jonas, W. B. (2011). Reframing pkacebo in research and practice. Philosophical 
transactions, 366(1572). 1896-1904. doi:  10.1098/rstb.2010.0405 
Kaptchuk, T. J., Friedlander, E., Kelley, J.M., Norma Sanchez, M.,Kokkotou, E., Singer, J. 
P., Kowalczykowski, M., Miller, F.G., Kirsch, I., & Lembo, A. J. (2010). Placebos without 
Deception: A Randomized Controlled Trial in Irritable Bowel Syndrome. PLoS ONE, 5(12) 
doi:10.1371/journal.pone.0015591 
Kenealy, T., & Arroll, B. (2013). Antibiotics for the common cold and acute purulent 
rhinitis. Cochrane Database of Systematic Reviews, 4(6). doi: 
10.1002/14651858.CD000247.pub3 
Kermen, R., Hickner, J., Brody, H., & Hasham, I. (2010). Family physicians believe the 
placebo effect is therapeutic but often use real drugs as placebos. Family Medicine, 42(9). 636-
642.  
Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. 
(2008). Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food 
and Drug Adminstration. PLoS Medicine, 5(2). doi: 10.1371/journal.pmed.0050045. 
Kirsch, I. (2013). The placebo effect revisited: Lessons learned to date. Complementary 
Therapies in Medicines. http://dx.doi.org/10.1016/j.ctim.2012.12.003 
OPEN-LABEL PLACEBO ATTITUDES  
45 
 
Lyon, M. L. (1993). Psychoneuroimmunology: The problem of the situatedness of illness and 
the conceptualization of healing. Culture, medicine and psychiatry, 17(1), 77- 97.  
Kisaalita, N. R., Roditi, D., & Robinson, M. E. (2011). Factors affecting placebo 
acceptability: deception, outcome, and disease severity. The Journal of Pain, 12(8), 920-926. 
https://doi.org/10.1016/j.jpain.2011.02.353 
Kisaalita, N., Staud, R., Hurley, R., & Robinson, M. Placebo use in pain management: The 
role of medical context, treatment efficacy, and deception in determining placebo acceptability. 
Pain, 155(12). 2638-2845. doi: 10.1016/j.pain.2014.09.029. 
Le Roux, E., Powell, K., Banks, J. B., & Ridd, M. J. (2018). GPs’ experiences of diagnosing 
and managing childhood eczema: a qualitative study in primary care. British Journal of General 
Practice, 68(667). oi:  10.3399/bjgp18X694529 
Li, L., Li, Y., & Zheng, Q. (2017). High placebo response rates hamper the discovery of 
antidepressants for depression in children and adolescents. The American Journal of Psychiatry, 
174(7), 696-697. https://doi-org.proxy.library.adelaide.edu.au/10.1176/appi.ajp.2017.17030347 
Lichtenberg, P., Heresco-Levy, U., & Nitzan, U. (2004). The ethics of the placebo in clinical 
practice. Journal of Medical Ethics 30, 551-554. http://dx.doi.org/10.1136/jme.2002.002832 
Lynoe, N., Mattsson, B., & Sandlund, M. (1993). The attitudes of patients and physicians 
towards placebo treatment – A comparative study. Social Science & Medicine, 36(6), 767-774. 
https://doi.org/10.1016/0277-9536(93)90037-5 
Medical Board of Australia (2018, June). Statistics. Registration Data. Retrieved from 
https://www.medicalboard.gov.au/news/statistics.aspx 
OPEN-LABEL PLACEBO ATTITUDES  
46 
 
Meissner, K., Hofner, L., Fassler, M., & Linde, K. (2012). Widespread use of pure and 
impure placebo interventions by GPs in Germany. Family Practice, 29(1), 79-85. 
https://doi.org/10.1093/fampra/cmr045 
Morris, C. J., Cantril, J. A., & Weiss, M. C. (2001). GP survey response rate: a miscellany of 
influencing factors. Family Practice, 18. 454-456 
Mundt, J. M., Roditi, D., & Robinson, M. E. (2017). A comparison of deceptive and non-
deceptive placebo analgesia: efficacy and ethical consequences. Annals of Behavioural Medicine, 
51. 307-315. DOI 10.1007/s12160-016-9854-0 
National Center for Health Statistics (2018, Jul). The number of practicing primary care 
physicians in the United States. Agency for Healthcare Research and Quality. Retrieved from 
https://www.ahrq.gov/research/findings/factsheets/primary/pcwork1/index.html 
Nizan, U., & Lichtenberg, P. (2004). Questionnaire survey on use of placebo. BMJ, 
329(7472). doi: 10.1136/bmj.38236.646678.55 
Olesen, F. (2015) Beyond the placebo: understanding the therapeutic context. British Journal 
of General Practice, 65(630), 6-7.  https://doi-
org.proxy.library.adelaide.edu.au/10.3399/bjgp15X683017 
Park, L. C., & Covi, U. (1965). Nonblind Placebo Trial. General Psychiatry, 12, 336-345. 
Price, D. D., Finniss, D. G., & Benedetti, F. (2008). A comprehensive review of the placebo 
effect: recent advances and current thought. Annual Reviews Psychology, 59, 565-590. doi: 
10.1146/annurev.psych.59.113006.095941 
Quinn, V. F., & Colagiuri, B. (2015). Placebo interventions for nausea: a systematic review. 
Annals of Behavioural Medicine, 49(3). 449-462. doi: 10.1007/s12160-014-9670-3. 
OPEN-LABEL PLACEBO ATTITUDES  
47 
 
Schaefer, M., Sahin, T., & Berstecher, B. (2018). Why do open-label placebos work? A 
randomized controlled trial of an open-label placebo induction with and without extended 
information about the placebo effect in allergic rhinitis. PLoS ONE, 13(3). doi: 
10.1371/journal.pone.0192758 
Shah, K. N., Panchal, D. J., Vyas, B. M., & Patel, V. J. (2009) Use of placebo: Knowledge, 
attitude and practice among medical practitioners. Indian Journal of Medical Sciences, 63(10), 
472-473. doi: 10.4103/0019-5359.57640 
Sherman, R., & Hickner, J. (2008). Academic physicians use placebos in clinical practice and 
believe in the mind-body connection. Journey of General Internal Medicine, 23(1), 7-10. 
Slauson – Blevins, K., & Johnson, K. M. (2016). Doing gender, doing surveys? Women’s 
gatekeeping and men’s non-participation in multi-actor reproductive surveys. Sociological 
Inquiry, 86(3). https://doi-org.proxy.library.adelaide.edu.au/10.1111/soin.12122 
Sonder. Retrieved from http://sonder.net.au 
Templeton, L. (1997). Survey general practitioners: Does a low response rate matter? British 
Journal of General Practice, 47(415), 91-94. 
Turner, T., & Connolly, K. (2018, April 18). Drug Side Effects & Medical Device 
Complications. Retrieved from https://www.drugwatch.com/side-effects/ 
Turner, J. A., Deyo, R. A., Loeser, J. D., Von Korff, M., & Fordyce, W. E. (1994). The 
importance of placebo effects in pain treatment and re- search. Journal of the American Medical 
Association, 271, 1609–1614. 
Ventola, C. L. (2015). The antibiotic resistance crisis. Pharmacy and Therapeutics, 40(4). 
277-283. 
OPEN-LABEL PLACEBO ATTITUDES  
48 
 
Ward, K. E., Archambault, R., & Mersfelder, T. L. (2010). Severe adverse skin reactions to 
nonsteroidal antiinflammatory drugs: A review of the literature. American Journal of Health-
System Pharmacy, 67(3). 206–213. doi: 10.2146/ajhp080603. 
Wartolowska, K., Beard, D. J., & Carr, A. J. (2014). Attitudes and beliefs about placebo 
survey among orthopaedic shoulder surgeons in the United Kingdom. PLoS ONE, 9(3). doi: 
10.1371/journal.pone.009169 
Wells, R. E., & Kaptchuck, T. J. (2012). To tell the truth, the whole truth, may do patients 
harm: The problem of nocebo effect for informed consent. American Journal of Bioethics, 12(3)/ 
22-29. https://doi.org/10.1080/15265161.2011.652798 
Wiebe, E. R., Kaczorowski, J., & MacKay, J. (2012). Why are response rates in clinician 
surveys declining? Canada Family Physician, 58(4). 
Winkelman, M. (2010). Shamanism: A biopsychosocial paradigm of consciousness and 
healing Praeger. 
World Health Organisation (1948). Retrieved from WHO definition of health? Retrieved 
from http://www.who.int/suggestions/faq/en/ 
Yeung, V., Sharpe, L., Glozier, N., Hackett, M. L., & Colagiuri, B. (2018). A systematic 
review and meta-analysis of placebo versus no treatment for insomnia symptoms. Sleep 
Medicine Reviews, 38, 17-27. http://doi.org/10.1016/j/smrv.2017.03.006 
Zimba, C. G., & Buggie, S. E. (1993). An experimental study of the placebo effect in African 
traditional medicine. Behavioural Medicine, 19(3), 103-109. doi: 
10.1080/08964289.1993.9935178 








You are invited to participate in the research project investigating the attitudes of general 
practitioners towards open-label placebos, described below. 
 
What is the project about? 
Current literature looking at placebos and their effects support the idea that they can be 
beneficial for patients in clinical settings (outside of trials). Thus, it is important to determine 
under what conditions general practitioners in Australia think it is acceptable to provide 
placebos (if any), as well as exploring their current knowledge and experience of placebos, 
given with and without deceit. This project will explore these ideas through an online survey.  
 
Who is undertaking the project? 
This project is being conducted by Dr Elise Devlin PhD, Lecturer, XX XXXX B. 
Psychological Science, Honours candidate in the School of Psychology, and Dr. Oliver Frank 
MBBS PhD FRACGP FACHI, University Senior Research Fellow, Discipline of General 
Practice, Adelaide Medical School.  
 
Why am I being invited to participate? 
You are being invited as you are a practicing general practitioner in Australia.  
 
What am I being invited to do? 
You are being invited to participate in an anonymous online survey answering questions in 
relation to placebos, placebo effects and open-label placebos.  
 
How much time will my involvement in the project take? 
The involvement in the project is estimated to take between 10 and 15 minutes. 
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Email: XX XXX 
 
What if I have a complaint or any concerns? 
 
The study has been approved by the School of Psychology: Human Research Ethics Sub-
Committee (approval number H-2018-35). This research project will be conducted according 
to the NHMRC National Statement on Ethical Conduct in Human Research (2007). If you 
have questions or problems associated with the practical aspects of your participation in the 
project, or wish to raise a concern or complaint about the project, then you should consult the 
Principal Investigator. If you wish to speak with an independent person regarding concerns or 
a complaint, the University’s policy on research involving human participants, or your rights 
as a participant, please contact Professor Paul Delfabbro on:  
Phone: (08) 8313 4936  
Email:    paul.delfabbro@adelaide.edu.au 
Any complaint or concern will be treated in confidence and fully investigated. You will be 
informed of the outcome. 
 
If I want to participate, what do I do? 
Participation is purely voluntary and can be undertaken by completing the following consent 
form and online survey.  
 
Yours sincerely, 
Dr Elise Devlin 
XX XXXX  





















Email and Facebook Post  
To Whom It May Concern.  
I seek your help with a research project investigating the attitudes of general practitioners towards 
open-label placebos. This study is being conducted as part of an Honours project and aims to 
determine under what conditions (if any) general practitioners in Australia think it is acceptable to 
provide placebo medicines, as well as exploring their current knowledge and experience of placebo 
medicines, given with or without deceit.  
 
The survey will take 10-15 minutes to complete.  
 
Your participation in the survey is completely voluntary and anonymous, and your responses will 
be kept confidential. 
 





Thank you very much for your time and cooperation.  
Warm regards,  
XX XXX B. Psychological Science 
School of Psychology  
University of Adelaide 
 
 




Your views about the potential use of placebo medicines in clinical practice. Thanks to those 
members who have helped us by completing the survey. We are calling for more members to 
help us with this research. 
 
The original post generated a lot of interesting discussion, which you can find by searching for 
'placebo'. 
 
In my University role, I am co-supervising an Honours psychology student, whose research 
project is about the potential uses of placebo medicines. Increasing our understanding of the 
potential uses of placebo medicines could lead to some useful new therapeutic strategies. I hope 
that you will help in this research. XX XXXX says: 
* 
I seek your help with a research project investigating the attitudes of general practitioners 
towards open-label placebos. This study is being conducted as part of an Honours project and 
aims to determine under what conditions general practitioners in Australia think it is acceptable 
to provide placebo medicines, as well as exploring their current knowledge and experience of 
placebo medicines, given with or without deceit. 
 
The survey will take 10-15 minutes to complete.  
 
Your participation in the survey is completely voluntary and anonymous, and your responses will 
be kept confidential. More details are in the first page of our online survey. 
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Thank you very much for your time and cooperation. 
  
Warm regards, 
XX XXXX B. Psychological Science 
School of Psychology 
University of Adelaide 
